Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.30 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114792 | 1.00 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4CTLR9 | |
| SCHEMBL5128905 | 0.89 | PDE4D (0.34) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5117567 | 0.89 | PDE4D (0.34) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5112965 | 0.88 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CTLR9 | |
| SCHEMBL5118222 | 0.88 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CTLR9 | |
| SCHEMBL5116011 | 0.83 | PDE4D (0.36) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5124265 | 0.83 | PDE4D (0.36) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5121331 | 0.82 | PDE4A (0.35) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5120204 | 0.82 | PDE4A (0.35) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5118250 | 0.82 | PDE4D (0.36) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167316-A1 | 6-Heteroaryl-1,2,3,4,4A, 10B-Hexahydrophenanthridines as Pde4-Inhibitors for the Treatment of Inflammatory Disorders | ALTANA PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167316-A1 | 6-Heteroaryl-1,2,3,4,4A, 10B-Hexahydrophenanthridines as Pde4-Inhibitors for the Treatment of Inflammatory Disorders | PDE4A, PDE4B, PDE4C | PDE4D 6/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.